Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun 5;2(3):155-7.
doi: 10.1111/j.2040-1124.2011.00125.x.

Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications

Yasuhiko Yamamoto  1 , Hiroshi Yamamoto  1
Affiliations

Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications

Yasuhiko Yamamoto et al. J Diabetes Investig. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Receptor for advanced glycation end‐products (RAGE) as a member of pattern‐recognition receptors (PRR) participating in inflammation and diabetic vascular complications. AGE, advanced glycation end‐products; AOPP, advanced oxidation protein products; esRAGE, endogenous secretory receptor for advanced glycation end‐products; HMGB1, high‐mobility group box protein 1; LPS, lipopolysaccharides; sRAGE, soluble receptor for advanced glycation end‐products; TLR, toll‐like receptors.
See this image and copyright information in PMC

References

    1. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE‐overexpressing mice. J Clin Invest 2001; 108: 261–268 - PMC - PubMed
    1. Myint KM, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low‐molecular weight heparin. Diabetes 2006; 55: 2510–2522 - PubMed
    1. Matsumoto S, Yoshida T, Murata H, et al. Solution structure of the variable‐type domain of the receptor for advanced glycation end products: new insight into AGE‐RAGE interaction. Biochemistry 2008; 47: 12299–12311 - PubMed
    1. Li J, Qu X, Yao J, et al. Blockade of endothelial‐mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin‐induced diabetic nephropathy. Diabetes 2010; 59: 2612–2624 - PMC - PubMed
    1. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end‐products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes‐induced vascular injury. Biochem J 2003; 370: 1097–1109 - PMC - PubMed

LinkOut - more resources